PRAME Antikörper (AA 21-509)

Produktnummer ABIN7600624

Der Kaninchen Polyklonal Anti-PRAME-Antikörper wurde für WB und ELISA validiert. Er ist geeignet, PRAME in Proben von Human zu detektieren.

Kurzübersicht für PRAME Antikörper (AA 21-509) (ABIN7600624)

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PRAME Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-PRAME Antikörper

Bindungsspezifität: AA 21-509

Verwendungszweck: Anti-PRAME Picoband® Antibody

Kreuzreaktivität (Details): No cross-reactivity with other proteins.

Produktmerkmale: Anti-PRAME Picoband® Antibody (ABIN7600624). Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E.coli-derived human PRAME recombinant protein (Position: T21-N509).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.25-0.5 μg/mL, Human
ELISA, 0.1-0.5 μg/mL, -
1. Epping, M. T., Wang, L., Edel, M. J., Carlee, L., Hernandez, M., Bernards, R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122: 835-847, 2005. 2. Ikeda, H., Lethe, B., Lehmann, F., van Baren, N., Baurain, J.-F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., Coulie, P. G. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199-208, 1997. 3. van Baren, N., Chambost, H., Ferrant, A., Michaux, L., Ikeda, H., Millard, I., Olive, D., Boon, T., Coulie, P. G. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Brit. J. Haemat. 102: 1376-1379, 1998.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na₂HPO₄, 0.05 mg NaN₃.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Details zu PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Andere Bezeichnung: PRAME

Hintergrund:

Synonyms: Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, OIP-4, Preferentially expressed antigen of melanoma, PRAME, MAPE

Tissue Specificity: Detected in brain, gastric carcinoma, lung, ovary, skeletal muscle, umbilical cord blood and a cell line derived from kidney proximal tubule epithelium.

Background: Melanoma antigen preferentially expressed in tumors is a protein that in humans is encoded by the PRAME gene. It is mapped to 22q11.22. This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants.

Molekulargewicht: 58 kDa

Gen-ID: 23532

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding